Reduced-dose IMRT with cisplatin meets predetermined benchmarks for PFS and swallowing-related QOL
(PHYSorg.com Medicine & Health)

Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer. These results were highlighted during the plenary session at the American Society for Radiation Oncology`s (ASTRO) Annual Meeting in September 2019 and this presentation was the recipient of ASTRO and ABR Foundation`s Steven A. Leibel Memorial Award at the Meeting.